Journey Medical annual stock-based compensation
2020
2021
2022
2023
2024
2025
Journey Medical Stock-Based Compensation Growth & History (DERM)
Journey Medical's stock-based compensation was $6.3M for fiscal 2025.
View full Journey Medical company overviewJourney Medical annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.3M | $190,000 | +3.12% |
| 2024 | 2024-12-31 | $6.1M | $3.5M | +134.00% |
| 2023 | 2023-12-31 | $2.6M | −$1.8M | −41.11% |
| 2022 | 2022-12-31 | $4.4M | $2.0M | +79.44% |
| 2021 | 2021-12-31 | $2.5M | $2.3M | +1511.76% |
| 2020 | 2020-12-31 | $153,000 | — | — |
Journey Medical quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.4M | $101,000 | +7.56% |
| Q1 2026 | 2026-03-31 | $989,000 | −$334,000 | −25.25% |
| Q4 2025 | 2025-12-31 | $1.8M | $397,000 | +28.81% |
| Q3 2025 | 2025-09-30 | $1.9M | $214,000 | +13.05% |
| Q2 2025 | 2025-06-30 | $1.3M | −$338,000 | −20.19% |
| Q1 2025 | 2025-03-31 | $1.3M | −$83,000 | −5.90% |
| Q4 2024 | 2024-12-31 | $1.4M | $849,000 | +160.49% |
| Q3 2024 | 2024-09-30 | $1.6M | $1.1M | +193.91% |
| Q2 2024 | 2024-06-30 | $1.7M | $801,000 | +91.75% |
| Q1 2024 | 2024-03-31 | $1.4M | $760,000 | +117.65% |
| Q4 2023 | 2023-12-31 | $529,000 | −$911,000 | −63.26% |
| Q3 2023 | 2023-09-30 | $558,000 | −$880,000 | −61.20% |
| Q2 2023 | 2023-06-30 | $873,000 | $99,000 | +12.79% |
| Q1 2023 | 2023-03-31 | $646,000 | −$127,000 | −16.43% |
| Q4 2022 | 2022-12-31 | $1.4M | −$985,000 | −40.62% |
| Q3 2022 | 2022-09-30 | $1.4M | $1.4M | +17875.00% |
| Q2 2022 | 2022-06-30 | $774,000 | $763,000 | +6936.36% |
| Q1 2022 | 2022-03-31 | $773,000 | $751,000 | +3413.64% |
| Q4 2021 | 2021-12-31 | $2.4M | — | — |
| Q3 2021 | 2021-09-30 | $8,000 | — | — |
| Q2 2021 | 2021-06-30 | $11,000 | — | — |
| Q1 2021 | 2021-03-31 | $22,000 | — | — |
Journey Medical stock-based compensation trends
Over the last five fiscal years, Journey Medical's stock-based compensation increased from $153,000 to $6.3M, a change of $6.1M. The latest reported quarter, Q2 2026, shows $1.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Journey Medical source filings ↗